Andere Sprachen Lantheus Holdings, Inc.

Aktien

A117UE

US5165441032

LNTH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 09.05.2024			% 5 Tage	% 1. Jan.
75,9 ^USD	+1,87 %		-2,92 %	+22,42 %

03.05.	LANTHEUS HOLDINGS, INC. : Bewertung von Truist Securities zum Kaufen erhalten	ZM
02.05.	Lantheus-Aktien steigen nach höherem bereinigtem Gewinn und Umsatz in Q1; Prognose für 2024 angehoben	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lantheus Shares Rise After Reporting Higher Q1 Adjusted Earnings, Revenue; 2024 Guidance Raised	02.05.
Lantheus to Seek M&A Opportunities	02.05.
Lantheus Holdings, Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024	02.05.
Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024	02.05.
Lantheus Holdings: Q1 Earnings Snapshot	02.05.
(LNTH) LANTHEUS HOLDINGS Sees Q2 EPS Range $1.81 - $1.86	02.05.
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 Revenue $370M	02.05.
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q1 EPS $1.69	02.05.
Lantheus Reports First Quarter 2024 Financial Results	02.05.
Lantheus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time	18.04.
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time	18.04.
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	07.03.
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	06.03.
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024	05.03.
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients	04.03.
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients	04.03.
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients	04.03.
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	04.03.
Lantheus Names Amanda Morgan Chief Commercial Officer	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lantheus Holdings, Inc.

Aktien

A117UE

US5165441032

LNTH

Andere Sprachen

Filter